| Year |
Citation |
Score |
| 2023 |
Parast L, Tian L, Wei LJ. Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck. Jama Oncology. PMID 37991750 DOI: 10.1001/jamaoncol.2023.5401 |
0.507 |
|
| 2023 |
Jhund PS, Claggett BL, Talebi A, Butt JH, Gasparyan SB, Wei LJ, McCaw ZR, Wilderäng U, Bengtsson O, Desai AS, Petersson M, Langkilde AM, de Boer RA, Hernandez AF, Inzucchi SE, et al. Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial. Jama Cardiology. PMID 37099283 DOI: 10.1001/jamacardio.2023.0711 |
0.37 |
|
| 2023 |
Wang X, Claggett BL, Tian L, Malachias MVB, Pfeffer MA, Wei LJ. Quantifying and Interpreting the Prediction Accuracy of Models for the Time of a Cardiovascular Event-Moving Beyond C Statistic: A Review. Jama Cardiology. PMID 36723915 DOI: 10.1001/jamacardio.2022.5279 |
0.412 |
|
| 2022 |
Claggett BL, McCaw ZR, Tian L, McMurray JJV, Jhund PS, Uno H, Pfeffer MA, Solomon SD, Wei LJ. Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes. Nejm Evidence. 1. PMID 37645407 DOI: 10.1056/evidoa2200047 |
0.49 |
|
| 2022 |
Huang B, Sun R, Claggett B, Tian L, Ludmir EB, Wei LJ. Handling Informative Premature Treatment or Study Discontinuation for Assessing Between-Group Differences in a Comparative Oncology Trial. Jama Oncology. PMID 35980612 DOI: 10.1001/jamaoncol.2022.2394 |
0.429 |
|
| 2022 |
McCaw ZR, Kim DH, Wei LJ. Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations. Jnci Cancer Spectrum. 6. PMID 35699499 DOI: 10.1093/jncics/pkac007 |
0.317 |
|
| 2021 |
McCaw ZR, Claggett BL, Tian L, Solomon SD, Berwanger O, Pfeffer MA, Wei LJ. Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks: A Review. Jama Cardiology. PMID 34851356 DOI: 10.1001/jamacardio.2021.4932 |
0.437 |
|
| 2021 |
McCaw ZR, Tian L, Wei J, Claggett BL, Bretz F, Fitzmaurice G, Wei LJ. Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies. Statistics in Medicine. 40: 6235-6242. PMID 34783094 DOI: 10.1002/sim.8971 |
0.449 |
|
| 2020 |
McCaw ZR, Tian L, Sheth KN, Hsu WT, Kimberly WT, Wei LJ. Selecting appropriate endpoints for assessing treatment effects in comparative clinical studies for COVID-19. Contemporary Clinical Trials. 106145. PMID 32927092 DOI: 10.1016/J.Cct.2020.106145 |
0.38 |
|
| 2020 |
Ludmir EB, McCaw ZR, Fuller CD, Wei LJ. Progression-free survival in the ICON8 trial. Lancet (London, England). 396: 756. PMID 32919510 DOI: 10.1016/S0140-6736(20)31175-2 |
0.33 |
|
| 2020 |
Campbell C, Barohn RJ, Bertini E, Chabrol B, Comi GP, Darras BT, Finkel RS, Flanigan KM, Goemans N, Iannaccone ST, Jones KJ, Kirschner J, Mah JK, Mathews KD, McDonald CM, ... ... Wei LJ, et al. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. Journal of Comparative Effectiveness Research. PMID 32851872 DOI: 10.2217/Cer-2020-0095 |
0.31 |
|
| 2020 |
McCaw ZR, Tian L, Vassy JL, Ritchie CS, Lee CC, Kim DH, Wei LJ. How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19. Annals of Internal Medicine. PMID 32634024 DOI: 10.7326/M20-4044 |
0.437 |
|
| 2020 |
Huang B, Tian L, McCaw ZR, Luo X, Talukder E, Rothenberg M, Xie W, Choueiri TK, Kim DH, Wei LJ. Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies. Annals of Internal Medicine. PMID 32628533 DOI: 10.7326/M20-0104 |
0.351 |
|
| 2020 |
Huang B, Wei LJ, Ludmir EB. Estimating Treatment Effect as the Primary Analysis in a Comparative Study: Moving Beyond Value. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1903111. PMID 32315271 DOI: 10.1200/Jco.19.03111 |
0.307 |
|
| 2020 |
Tian L, Jin H, Uno H, Lu Y, Huang B, Anderson KM, Wei LJ. On the empirical choice of the time window for restricted mean survival time. Biometrics. PMID 32061098 DOI: 10.1111/Biom.13237 |
0.321 |
|
| 2019 |
Uno H, Schrag D, Kim DH, Tang D, Tian L, Rugo HS, Wei LJ. Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes. Jnci Cancer Spectrum. 3: pkz058. PMID 32337484 DOI: 10.1093/Jncics/Pkz058 |
0.429 |
|
| 2019 |
McCaw ZR, Yin G, Wei LJ. Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies. Circulation. 140: 1366-1368. PMID 31634007 DOI: 10.1161/Circulationaha.119.040680 |
0.369 |
|
| 2019 |
Rabideau DJ, Kim DH, Wei LJ. Using Confidence Intervals to Quantify Statistical and Clinical Evidence for the Treatment Effect in a Comparative Study-Moving Beyond P Values. Jama Otolaryngology-- Head & Neck Surgery. PMID 31621806 DOI: 10.1001/Jamaoto.2019.3057 |
0.356 |
|
| 2019 |
Manner DH, Battioui C, Hantel S, Beasley BN, Wei LJ, Geiger MJ, Turner JR, Abt M. Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development. American Heart Journal. 215: 178-186. PMID 31349109 DOI: 10.1016/J.Ahj.2019.05.016 |
0.358 |
|
| 2019 |
Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani HA, Hennessy B, Jansa P, Mehta S, Perchenet L, Pulido T, Rosenberg D, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, ... ... Wei LJ, et al. Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circulation. Cardiovascular Quality and Outcomes. 12: e005095. PMID 31109190 DOI: 10.1161/Circoutcomes.118.005095 |
0.386 |
|
| 2019 |
Claggett B, Uno H, Wei LJ. Unifying Design and Analysis for Superiority and Noninferiority Trials With Appropriate End Point. Jama Surgery. PMID 30785628 DOI: 10.1001/Jamasurg.2018.5852 |
0.476 |
|
| 2019 |
Claggett B, Pocock S, Wei LJ, Pfeffer MA, McMurray JJV, Solomon SD. Response by Claggett et al to Letter Regarding Article, "Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials". Circulation. 139: 422-423. PMID 30640547 DOI: 10.1161/Circulationaha.118.038478 |
0.416 |
|
| 2018 |
Claggett B, Tian L, McCaw ZR, Takeuchi M, Wei LJ. Sex as a predictor of response to cancer immunotherapy. The Lancet. Oncology. 19: e377. PMID 30102227 DOI: 10.1016/S1470-2045(18)30517-5 |
0.341 |
|
| 2018 |
Claggett B, Tian L, Wei LJ. Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma. Jama Oncology. PMID 30098159 DOI: 10.1001/Jamaoncol.2018.3483 |
0.431 |
|
| 2018 |
Claggett B, Tian L, Fu H, Solomon SD, Wei LJ. Quantifying the totality of treatment effect with multiple event-time observations in the presence of a terminal event from a comparative clinical study. Statistics in Medicine. PMID 30047148 DOI: 10.1002/Sim.7907 |
0.567 |
|
| 2018 |
Uno H, Tian L, Wei LJ. Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis. Jama Oncology. PMID 29931103 DOI: 10.1001/Jamaoncol.2018.1087 |
0.312 |
|
| 2018 |
Horiguchi M, Tian L, Uno H, Cheng S, Kim DH, Schrag D, Wei LJ. Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study. Jama Oncology. PMID 29801103 DOI: 10.1001/Jamaoncol.2018.0518 |
0.305 |
|
| 2018 |
Huang B, Tian L, Talukder E, Rothenberg M, Kim DH, Wei LJ. Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study. Jama Oncology. PMID 29710201 DOI: 10.1001/Jamaoncol.2018.0275 |
0.31 |
|
| 2018 |
Uno H, Claggett B, Tian L, Fu H, Huang B, Kim DH, Wei LJ. Adding A New Analytical Procedure With Clinical Interpretation in the Tool Box of Survival Analysis. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29617717 DOI: 10.1093/Annonc/Mdy109 |
0.42 |
|
| 2018 |
Zhao L, Tian L, Claggett B, Pfeffer M, Kim DH, Solomon S, Wei LJ. Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks. Jama Cardiology. PMID 29541747 DOI: 10.1001/Jamacardio.2018.0127 |
0.461 |
|
| 2018 |
Horiguchi M, Uno H, Wei LJ. Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017759829. PMID 29373099 DOI: 10.1200/Jco.2017.75.9829 |
0.322 |
|
| 2018 |
Horiguchi M, Uno H, Wei LJ. Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017760983. PMID 29337638 DOI: 10.1200/Jco.2017.76.0983 |
0.313 |
|
| 2017 |
Angelidou KN, Palumbo P, Lindsey J, Violary A, Archary M, Barlow L, Claggett B, Hughes M, Wei LJ. Defining Study Outcomes That Better Reflect Individual Response to Treatment. The Pediatric Infectious Disease Journal. PMID 29189677 DOI: 10.1097/Inf.0000000000001766 |
0.497 |
|
| 2017 |
Pak K, Uno H, Kim DH, Tian L, Kane RC, Takeuchi M, Fu H, Claggett B, Wei LJ. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. Jama Oncology. PMID 28975263 DOI: 10.1001/Jamaoncol.2017.2797 |
0.555 |
|
| 2017 |
Kim DH, Uno H, Wei LJ. Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results. Jama Cardiology. PMID 28877311 DOI: 10.1001/Jamacardio.2017.2922 |
0.372 |
|
| 2017 |
Hasegawa T, Claggett B, Tian L, Solomon SD, Pfeffer MA, Wei L. The Myth of Making Inferences for an Overall Treatment Efficacy with Data from Multiple Comparative Studies Via Meta-Analysis Statistics in Biosciences. 9: 284-297. DOI: 10.1007/S12561-016-9179-3 |
0.539 |
|
| 2016 |
Hasegawa T, Uno H, Wei LJ. Neratinib after trastuzumab in patients with HER2-positive breast cancer. The Lancet. Oncology. 17: e176. PMID 27301038 DOI: 10.1016/S1470-2045(16)00165-0 |
0.341 |
|
| 2015 |
Li J, Zhao L, Tian L, Cai T, Claggett B, Callegaro A, Dizier B, Spiessens B, Ulloa-Montoya F, Wei LJ. A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studies. Biometrics. PMID 26689167 DOI: 10.1111/Biom.12461 |
0.604 |
|
| 2015 |
Zhao L, Claggett B, Tian L, Uno H, Pfeffer MA, Solomon SD, Trippa L, Wei LJ. On the restricted mean survival time curve in survival analysis. Biometrics. PMID 26302239 DOI: 10.1111/Biom.12384 |
0.432 |
|
| 2015 |
Uno H, Tian L, Claggett B, Wei LJ. A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves. Statistics in Medicine. PMID 26194988 DOI: 10.1002/Sim.6591 |
0.429 |
|
| 2015 |
Uno H, Wittes J, Fu H, Solomon SD, Claggett B, Tian L, Cai T, Pfeffer MA, Evans SR, Wei LJ. Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. Annals of Internal Medicine. PMID 26054047 DOI: 10.7326/M14-1741 |
0.58 |
|
| 2015 |
Claggett B, Tian L, Castagno D, Wei LJ. Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints. Biostatistics (Oxford, England). 16: 60-72. PMID 25122189 DOI: 10.1093/Biostatistics/Kxu037 |
0.572 |
|
| 2014 |
Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, Schrag D, Takeuchi M, Uyama Y, Zhao L, Skali H, Solomon S, Jacobus S, Hughes M, Packer M, ... Wei LJ, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2380-5. PMID 24982461 DOI: 10.1200/Jco.2014.55.2208 |
0.464 |
|
| 2013 |
Zhao L, Tian L, Cai T, Claggett B, Wei LJ. EFFECTIVELY SELECTING A TARGET POPULATION FOR A FUTURE COMPARATIVE STUDY. Journal of the American Statistical Association. 108: 527-539. PMID 24058223 DOI: 10.1080/01621459.2013.770705 |
0.594 |
|
| 2013 |
Cai T, Tian L, Lloyd-Jones D, Wei LJ. Evaluating subject-level incremental values of new markers for risk classification rule. Lifetime Data Analysis. 19: 547-67. PMID 23807696 DOI: 10.1007/S10985-013-9272-6 |
0.401 |
|
| 2013 |
Claggett B, Wei LJ, Pfeffer MA. Moving beyond our comfort zone European Heart Journal. 34: 869-871. PMID 23329152 DOI: 10.1093/Eurheartj/Ehs485 |
0.532 |
|
| 2013 |
Uno H, Tian L, Cai T, Kohane IS, Wei LJ. A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. Statistics in Medicine. 32: 2430-42. PMID 23037800 DOI: 10.1002/Sim.5647 |
0.45 |
|
| 2012 |
Tian L, Cai T, Zhao L, Wei LJ. On the covariate-adjusted estimation for an overall treatment difference with data from a randomized comparative clinical trial. Biostatistics (Oxford, England). 13: 256-73. PMID 22294672 DOI: 10.1093/Biostatistics/Kxr050 |
0.485 |
|
| 2011 |
Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, Bollu VK, Williams D, Wei LJ, DeAngelo DJ. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Current Medical Research and Opinion. 27: 1263-71. PMID 21524239 DOI: 10.1185/03007995.2011.576238 |
0.543 |
|
| 2011 |
Uno H, Cai T, Tian L, Wei LJ. Graphical procedures for evaluating overall and subject-specific incremental values from new predictors with censored event time data. Biometrics. 67: 1389-96. PMID 21504421 DOI: 10.1111/J.1541-0420.2011.01600.X |
0.474 |
|
| 2011 |
Uno H, Cai T, Pencina MJ, D'Agostino RB, Wei LJ. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Statistics in Medicine. 30: 1105-17. PMID 21484848 DOI: 10.1002/Sim.4154 |
0.485 |
|
| 2011 |
Claggett B, Wei LJ. Analytical issues regarding rosiglitazone meta-analysis. Archives of Internal Medicine. 171: 179-80; author reply. PMID 21263111 DOI: 10.1001/Archinternmed.2010.508 |
0.437 |
|
| 2011 |
Cai T, Tian L, Wong PH, Wei LJ. Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics (Oxford, England). 12: 270-82. PMID 20876663 DOI: 10.1093/Biostatistics/Kxq060 |
0.499 |
|
| 2011 |
Tian L, Wang R, Cai T, Wei LJ. The highest confidence density region and its usage for joint inferences about constrained parameters. Biometrics. 67: 604-10. PMID 20825392 DOI: 10.1111/J.1541-0420.2010.01486.X |
0.464 |
|
| 2010 |
Wang R, Tian L, Cai T, Wei LJ. Nonparametric inference procedure for percentiles of the random effects distribution in meta-analysis The Annals of Applied Statistics. 4: 520-532. DOI: 10.1214/09-AOAS280 |
0.417 |
|
| 2009 |
Tian L, Cai T, Pfeffer MA, Piankov N, Cremieux PY, Wei LJ. Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction. Biostatistics (Oxford, England). 10: 275-81. PMID 18922759 DOI: 10.1093/Biostatistics/Kxn034 |
0.475 |
|
| 2008 |
Tian L, Cai T, Wei LJ. Identifying subjects who benefit from additional information for better prediction of the outcome variables. Biometrics. 65: 894-902. PMID 18945268 DOI: 10.1111/J.1541-0420.2008.01125.X |
0.434 |
|
| 2007 |
Evans SR, Li L, Wei L. Data Monitoring in Clinical Trials Using Prediction Drug Information Journal. 41: 733-742. DOI: 10.1177/009286150704100606 |
0.337 |
|
| 2005 |
Chuang SK, Cai T, Douglass CW, Wei LJ, Dodson TB. Frailty approach for the analysis of clustered failure time observations in dental research. Journal of Dental Research. 84: 54-8. PMID 15615876 DOI: 10.1177/154405910508400109 |
0.361 |
|
| 2000 |
Cheng S, Wei L. Inferences for a semiparametric model with panel data Biometrika. 87: 89-97. DOI: 10.1093/Biomet/87.1.89 |
0.337 |
|
| 1999 |
Rogus JJ, Cai T, Wei L. Issues in genomic screening: critical values, sample sizes, and the ability to detect linkage. Genetic Epidemiology. 17. PMID 10597516 DOI: 10.1002/Gepi.13701707114 |
0.438 |
|
| 1998 |
Cheng SC, Fine JP, Wei LJ. Prediction of cumulative incidence function under the proportional hazards model Biometrics. 54: 219-228. PMID 9544517 DOI: 10.2307/2534009 |
0.491 |
|
| 1997 |
Yao Q, Wei LJ. Play the winner for phase II/III clinical trials. Statistics in Medicine. 15: 2413-23; discussion . PMID 8931210 DOI: 10.1002/(Sici)1097-0258(19961130)15:22<2413::Aid-Sim460>3.0.Co;2-N |
0.405 |
|
| Show low-probability matches. |